Prevalence of Long-term Respiratory Complications of Severe SARS-CoV-2 Pneumonia - COVID-19

Prevalence of Long-term Respiratory Complications of Severe SARS-CoV-2 Pneumonia

Studies performed after coronavirus epidemics (severe acute respiratory syndrome coronavirus, SARS-CoV and Middle East respiratory syndrome coronavirus, MERS-CoV) have shown a long-term impact on respiratory morbidity, musculoskeletal and psycho-social repercussions.

Patients with SARS-CoV pneumonia had fibrotic pulmonary sequelae at 45 days (lower DLCO in 27.3% of cases and radiological lesions in 21.5% of cases). In the MERS-CoV pneumonia study, patients had radiological sequelae in 33% of cases and the 12-month evaluation showed persistence of radiological abnormalities in 23.7% of the cases despite an improvement in respiratory function.

Clinical presentation and therapeutic management of severe SARS-CoV-2 infection are in part similar to those induced by SARS-CoV and MERS-CoV. Long-term respiratory complications are therefore expected.

Objective is to evaluate prevalence of long-term respiratory complications after severe SARS-CoV2 pneumonia.

Inclusion Criteria:

• Adult patient
• Patient with with severe SARS-CoV2 pneumonia
• Patient consenting to participate to the study
• Patient enrolled in the national healthcare insurance program

Exclusion Criteria:

• Patient under 18 years